The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Feasibility of Patient Selection and Treatment of Head-neck Cancer With Proton Therapy in Denmark
Official Title: DAHANCA Proton Feasibility Study
Study ID: NCT05423704
Brief Summary: A study to investigate feasibility of local selection of patients with squamous cell carcinoma of the pharynx or larynx using anticipated benefit of proton radiotherapy in reducing the risk of late dysphagia or xerostomia.
Detailed Description: In preparation for a randomised study in Denmark (DAHANCA 35) the feasibility of selecting newly diagnosed patients with squamous cell carcinoma of the pharynx or larynx for proton therapy at the local treatment centers is investigated. A proton and a photon doseplan is prepared for patients planned for primary radiotherapy . If proton radiotherapy reduces the anticipated absolute risk of dysphagia \>= grade 2 (DAHANCA scale and/or xerostomia \>= grade 2 (EORTC Head-Neck 35) with a clinical relevant value the patient is offered proton therapy at the Danish Center for Particle Therapy. The anticipated risk of xerostomia and dysphagia is estimated using Normal-Tissue Complication Models (NTCP). At least five patients from each of the six Danish centers are required in this feasibility study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aalborg University Hospital, Aalborg, , Denmark
Aarhus University Hospital, Aarhus, , Denmark
Danish Center for Particle Therapy, Aarhus, , Denmark
Rigshospitalet, Copenhagen, , Denmark
Herlev Hospital, Herlev, , Denmark
Næstved Hospital, Næstved, , Denmark
Odense University Hospital, Odense, , Denmark
Name: Jeppe Friborg, MD, PhD
Affiliation: Danish Head-Neck Cancer Group (DAHANCA)
Role: PRINCIPAL_INVESTIGATOR